Boston Scientific Investors Seek to Recover Losses After Disappointing Earnings

Robbins LLP Investigates Claims of Misleading Investors About Projected Revenue and Growth

Mar. 31, 2026 at 8:40pm

Got story updates? Submit your updates here. ›

A close-up view of a sleek, metallic medical device component floating on a plain white background, representing the abstract corporate strategy and financial risks facing Boston Scientific Corporation.A polished medical device component symbolizes the high-stakes financial risks facing Boston Scientific as it navigates increased competition and market share challenges.San Diego Today

Robbins LLP has filed a class action lawsuit on behalf of investors who purchased Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025 and February 3, 2026. The lawsuit alleges that Boston Scientific misled investors about its projected revenue outlook and anticipated growth, failing to disclose increased competition that was limiting the company's market share and growth potential.

Why it matters

This case highlights the importance of transparency and accurate financial reporting, especially for publicly traded medical device companies that investors rely on for growth and stability. The allegations raise concerns about Boston Scientific's risk management and ability to navigate a changing competitive landscape.

The details

According to the complaint, Boston Scientific had claimed it would 'continue to grow our share in the overall EP market' and maintain a growth trajectory at '2x the market.' However, the company failed to disclose that it was facing new competition that was eroding its U.S. Electrophysiology market share and limiting its growth potential. On February 4, 2026, Boston Scientific announced disappointing fourth quarter and full year 2025 results, including weaker-than-expected U.S. EP sales, and provided fiscal 2026 guidance that fell short of expectations. This news caused the company's stock price to decline over 17%.

  • The class period is July 23, 2025 to February 3, 2026.
  • On February 4, 2026, Boston Scientific announced its Q4 2025 and full year 2025 results, including weaker-than-expected U.S. EP sales, and provided fiscal 2026 guidance that fell short of expectations.

The players

Boston Scientific Corporation

A global medical device company that develops, manufactures, and markets products used across various medical specialties.

Robbins LLP

A law firm that has filed a class action lawsuit on behalf of Boston Scientific investors who purchased the company's stock during the class period.

Got photos? Submit your photos here. ›

What they’re saying

“Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025 and February 3, 2026.”

— Robbins LLP

What’s next

Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by May 4, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

The takeaway

This case highlights the importance of medical device companies providing accurate and transparent information to investors about their competitive landscape and growth prospects. Shareholders will be closely watching the outcome of this lawsuit and the impact it may have on Boston Scientific's future disclosures and risk management practices.